论文部分内容阅读
凝血因子Ⅷ是一种血浆蛋白,迄今虽然尚未被很好地描述,但与分子量2,000,000的蛋白质复合物有关。目前防治血友病 A 是静脉应用此蛋白质部分纯化的制剂。作者介绍一种载有Ⅷ因子的微脂粒的制剂,当其给血友病患者口服时可使血浆Ⅷ因子促凝血活性增高。根据 Veltkamp 氏法测定血浆Ⅷ因子浓度,并以百分比表示血浆池的Ⅷ因子浓度(n=30)。每一个标本测定4次。在开始时给予口服或静脉注射Ⅷ因
Factor Ⅷ is a plasma protein that up to now has not yet been well characterized but related to a 2,000,000 protein complex. Currently, prevention and treatment of hemophilia A is a partially purified preparation for intravenous application of this protein. The authors describe a formulation containing Ⅷ-factor liposomes that increases plasma factor VIII procoagulant activity when given orally to hemophiliacs. Plasma Factor VIII concentrations were determined according to the Veltkamp’s method and expressed as a percentage of Factor VIII concentration in the plasma pool (n = 30). Each specimen was measured 4 times. Oral or intravenous injection of Factor VIII was given initially